Sexual Health Peptides: PT-141 vs Kisspeptin

Overview

Peptides that target sexual function represent a distinct pharmacological approach from traditional treatments like PDE5 inhibitors (sildenafil/tadalafil). Rather than acting on vascular mechanisms, sexual health peptides modulate central nervous system pathways involved in sexual desire and arousal. Two peptides have received significant clinical attention: PT-141 (bremelanotide), which is FDA-approved under the brand name Vyleesi, and kisspeptin, a neuropeptide under active clinical investigation.

These two peptides work through fundamentally different neurobiological systems. PT-141 activates melanocortin-4 receptors (MC4R) in the brain, directly stimulating neural circuits associated with sexual arousal (Kingsberg & Woodard, 2021). Kisspeptin acts upstream on the hypothalamic-pituitary-gonadal (HPG) axis by stimulating gonadotropin-releasing hormone (GnRH) neurons, influencing both reproductive hormone release and limbic brain regions associated with sexual processing (Comninos et al., 2022).

The evidence base differs substantially between these two agents. PT-141 has completed Phase III randomized controlled trials with over 1,200 premenopausal women with hypoactive sexual desire disorder (HSDD), leading to FDA approval in June 2019 (Scott, 2019). Kisspeptin research is at an earlier stage, with published randomized clinical trials in both men and women demonstrating effects on sexual brain processing, but it has not entered Phase III development for any sexual health indication (Mills et al., 2023).

At a Glance

A quick-reference overview of peptides in this category — key facts, evidence level, and estimated cost.

Head-to-Head Comparison

Sources: FDA prescribing information for Vyleesi (bremelanotide); Kingsberg et al., 2017 (PT-141 Phase 3); Scott, 2019 (bremelanotide review); Comninos et al., 2017 (kisspeptin & sexual processing).

PT-141 (Bremelanotide / Vyleesi)

What It Is

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide derived from the melanocortin peptide Melanotan II. It was developed by Palatin Technologies and approved by the FDA in June 2019 under the brand name Vyleesi for the treatment of acquired, generalized HSDD in premenopausal women (Scott, 2019). It is marketed by AMAG Pharmaceuticals (later acquired by Covis Pharma).

Unlike PDE5 inhibitors that act on blood flow, bremelanotide acts centrally in the brain. It was the first medication approved for sexual desire (as opposed to arousal or erectile function) that works through a non-hormonal, non-vascular mechanism (Kingsberg & Woodard, 2021).

Mechanism of Action

Bremelanotide is a non-selective agonist of melanocortin receptors, with primary activity at the melanocortin-4 receptor (MC4R). MC4R is expressed in hypothalamic and limbic brain regions involved in sexual motivation and arousal. Activation of MC4R modulates dopaminergic and oxytocinergic pathways implicated in sexual desire (Kingsberg & Woodard, 2021).

The melanocortin system plays a broad role in energy homeostasis, inflammation, and sexual function. PT-141's activity at MC3R and MC1R (the receptor involved in pigmentation) accounts for some of its side effects, including transient skin darkening in some patients (Scott, 2019).

Clinical Evidence

The FDA approval was based on the RECONNECT trials — two Phase III, randomized, double-blind, placebo-controlled studies enrolling 1,247 premenopausal women with HSDD. Key findings:

• Statistically significant increase in desire score (measured by the Female Sexual Function Index desire domain) vs. placebo
• Statistically significant reduction in distress related to low desire (measured by the Female Sexual Distress Scale–Desire/Arousal/Orgasm item 13)
• Effects were modest but clinically meaningful per FDA review
• Approximately 25% of women reported a "meaningful" improvement vs. ~17% with placebo

Source: Goldstein et al., 2022; Scott, 2019.

In men: Earlier clinical trials studied PT-141 for erectile dysfunction. Phase II trials showed some efficacy in men with ED, including those who did not respond to sildenafil. However, development for male indications was not pursued to Phase III, and PT-141 is not FDA-approved for use in men (Goldstein et al., 2022).

Dosing Context

Vyleesi is administered as a subcutaneous injection via an autoinjector. It is used on an as-needed basis prior to anticipated sexual activity. Specific dosing should be determined by a qualified healthcare provider. The FDA label notes a maximum frequency of use and dose limitations due to the risk of blood pressure effects (Scott, 2019).

Side Effects

• Nausea — the most common side effect, reported in approximately 40% of patients in clinical trials. Generally transient but can be significant (Scott, 2019)
• Flushing — reported in ~20% of patients
• Headache — reported in ~11%
• Injection site reactions — pain, bruising at injection site
• Hyperpigmentation — darkening of skin (face, gums, breasts) reported with repeated use, related to MC1R activation. May not fully resolve after discontinuation
• Blood pressure — transient increases in blood pressure observed; Vyleesi is contraindicated in patients with uncontrolled hypertension or cardiovascular disease

Legal Status

• United States: FDA-approved prescription medication (Vyleesi). Available by prescription for premenopausal women with HSDD. Not a controlled substance.
• Europe: Not approved by the EMA. Bremelanotide is not authorized for marketing in EU member states.
• Compounded versions: Available through some compounding pharmacies and telehealth clinics, sometimes marketed toward men despite lack of FDA approval for male indications.

Cost

• Vyleesi (brand): Approximately $900–$1,000 per month at retail pricing for the autoinjector
• Insurance coverage: Variable; many insurers require prior authorization and may not cover it
• Compounded bremelanotide: Available at lower cost ($100–$300/month) through peptide clinics and compounding pharmacies, though quality and standardization vary

Kisspeptin

What It Is

Kisspeptin is a family of neuropeptides encoded by the KISS1 gene. The most studied form is kisspeptin-54 (formerly known as metastin), a 54-amino acid peptide that acts on the kisspeptin receptor (KISS1R, formerly GPR54). Kisspeptin was originally identified for its role as a metastasis suppressor in melanoma cells, but it was subsequently found to be a critical regulator of the hypothalamic-pituitary-gonadal axis (Mohammadi & Abdollahi, 2025).

Kisspeptin neurons in the hypothalamus are the primary upstream regulators of gonadotropin-releasing hormone (GnRH) neurons. Loss-of-function mutations in KISS1 or KISS1R cause hypogonadotropic hypogonadism — failure to enter puberty — demonstrating the peptide's essential role in reproductive biology (Comninos et al., 2022).

Mechanism of Action

Kisspeptin binds to KISS1R on GnRH neurons in the hypothalamus, stimulating pulsatile GnRH release, which in turn drives luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. This cascade activates gonadal hormone production (testosterone, estrogen).

Beyond hormonal effects, functional MRI studies have demonstrated that kisspeptin modulates activity in limbic brain regions involved in sexual arousal and emotional processing, including the amygdala, cingulate cortex, and globus pallidus. These effects appear to be at least partially independent of the hormonal changes, suggesting a direct central role in sexual processing (Mills et al., 2023).

Clinical Evidence

In women with HSDD: A randomized, double-blind, placebo-controlled crossover trial administered kisspeptin-54 intravenously to women with HSDD. The study found kisspeptin significantly increased sexual desire (as measured by a validated desire scale) compared to placebo, and enhanced brain activity in reward and sexual processing regions on fMRI (Comninos et al., 2022).

In men with HSDD: A randomized placebo-controlled trial in men with low sexual desire showed that kisspeptin-54 infusion enhanced sexual brain processing on fMRI and increased penile tumescence in response to erotic stimuli compared to placebo (Mills et al., 2023).

Limitations: All clinical studies to date have been relatively small (typically 20–40 participants per arm), conducted in single-center academic settings, and used intravenous administration. No Phase III trials have been conducted. The duration of effect and optimal dosing for clinical use have not been established (Mohammadi & Abdollahi, 2025).

Dosing Context

Kisspeptin is not approved for clinical use. In research settings, it has been administered as an intravenous infusion. Dosing for any potential clinical application should be determined by a qualified healthcare provider in the context of a clinical trial or supervised medical setting. Intranasal formulations are under investigation but have not been validated (Mohammadi & Abdollahi, 2025).

Side Effects

In published clinical trials, kisspeptin-54 has been reported as well-tolerated:

• Facial flushing — the most commonly reported side effect, generally mild and transient
• Injection/infusion site reactions — mild
• No significant cardiovascular effects reported in published trials
• No nausea reported at rates above placebo

However, the safety profile is based on limited short-term exposure in small trials. Long-term safety data does not exist (Comninos et al., 2022).

Legal Status

• United States: Not FDA-approved for any indication. Available as a research chemical. Not a controlled substance.
• Europe: Not approved by the EMA. Used in clinical research under institutional review.
• Other jurisdictions: Not approved for clinical use in any country as of this writing.
• Research chemical market: Kisspeptin-10 (a truncated 10-amino acid fragment) is available from peptide suppliers; kisspeptin-54 (the form used in clinical trials) is less commonly available.

Cost

• Not commercially available as a prescription medication
• Research-grade kisspeptin-10: Variable pricing from peptide suppliers, typically $50–$150 per vial
• Kisspeptin-54: More expensive to synthesize due to length; limited availability
• Note: Research-grade peptides are not manufactured to pharmaceutical standards and are not intended for human use

Sources & Further Reading

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.